Back to All NewsHologic to Acquire Cynosure
Posted By American Med Spa Association, Monday, February 27, 2017
Share
Hologic, a global healthcare and diagnostics company focused on woman’s health, announced Feb. 14, 2017, that it signed a definitive agreement to acquire all outstanding Cynosure shares, an equity value estimated at $1.65 billion.
The announcement comes the day after Allergan announced that it would acquire Zeltiq.
The Cynosure product portfolio includes popular brands SculpSure, the first FDA-cleared laser treatment for non-invasive body contouring, PicoSure and MonaLisa Touch.
"Acquiring Cynosure will accelerate our transformation into a higher-growth company by leveraging our core women's health expertise and OB/GYN channel leadership into an adjacent, cash-pay segment that is expanding at a low double-digit rate," Steve MacMillan, Hologic's chairman, president and chief executive officer, says in a press release announcing the deal. "We had identified medical aesthetics as an attractive and complementary growth opportunity through our strategic planning process, and are pleased to have agreed to acquire Cynosure, the best-in-class company in the space. Together, we can strengthen our shared focus on innovation, market-leading products with demonstrated clinical benefits and strong customer relationships. "
Read more at Dermatology Times >>
The announcement comes the day after Allergan announced that it would acquire Zeltiq.
The Cynosure product portfolio includes popular brands SculpSure, the first FDA-cleared laser treatment for non-invasive body contouring, PicoSure and MonaLisa Touch.
"Acquiring Cynosure will accelerate our transformation into a higher-growth company by leveraging our core women's health expertise and OB/GYN channel leadership into an adjacent, cash-pay segment that is expanding at a low double-digit rate," Steve MacMillan, Hologic's chairman, president and chief executive officer, says in a press release announcing the deal. "We had identified medical aesthetics as an attractive and complementary growth opportunity through our strategic planning process, and are pleased to have agreed to acquire Cynosure, the best-in-class company in the space. Together, we can strengthen our shared focus on innovation, market-leading products with demonstrated clinical benefits and strong customer relationships. "
Read more at Dermatology Times >>
